Surface Oncology in Clinical Trial Collaboration With Roche
June 04 2021 - 8:36AM
Dow Jones News
By Michael Dabaie
Surface Oncology Inc. on Friday said it is in a clinical trial
collaboration with Roche Holding AG to evaluate SRF388 in
combination with Roche's atezolizumab and bevacizumab in patients
with treatment-naive hepatocellular carcinoma.
The clinical-stage immuno-oncology company said atezolizumab
plus bevacizumab has been shown to significantly improve overall
survival and is the new standard of care for unresectable or
metastatic HCC. Surface said the addition of SRF388 to the proven
efficacy of the atezolizumab/bevacizumab regimen has the "potential
to further improve outcomes in this challenging disease."
Surface Oncology shares were up 4% to $9.42 in premarket
trading.
Surface Oncology also said Friday that SRF388 demonstrated
monotherapy activity in data being presented at the American
Society of Clinical Oncology Annual Meeting. Surface said SRF388
produced a partial response in a heavily pretreated patient with
lung cancer.
Preliminary SRF388 results indicate promising single-agent
activity in a heavily pretreated population, including a confirmed
partial response demonstrating 66% tumor shrinkage and symptomatic
improvement in a patient with squamous cell non-small-cell lung
carcinoma.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 04, 2021 08:29 ET (12:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024